Earnings call transcript: RBC Bearings Q4 2026 sees strong earnings, stock tumbles

RBC Bearings beat Q4 FY2026 expectations with adjusted EPS of $3.62 versus $3.32 consensus and revenue of $518 million versus $506.3 million, while net sales rose 18.3% year over year and adjusted EBITDA increased 21% to $168.9 million. A&D revenue surged 41.2% and backlog reached about $2.3 billion, but the stock fell 9.94% pre-market to $551.12 amid valuation concerns and a still-premium multiple. Management guided Q1 FY2027 revenue to $500-$510 million, implying 14.7%-17% growth, and said defense/space growth should outpace commercial aerospace.

Analysis

The market is signaling that the print is not the story; the story is the multiple. A business with accelerating defense/space content, expanding backlog, and visible de-leveraging usually deserves a rerate, but the current selloff suggests investors are already discounting near-perfect execution and are unwilling to pay up for growth that is increasingly tied to defense procurement cycles and a few very hot end markets. That creates an important second-order effect: the tighter the capacity, the more pricing power RBC has on incremental programs, but the less room there is for the market to tolerate any hiccup in titanium/aluminum supply or a delay in plant expansion.

The more interesting read-through is to primes and peers. If RBC is pushing mix toward higher-content missile and submarine work, it implies the entire defense supply chain is still in a catch-up phase, which should keep demand for specialized components, machine tools, and subcontract manufacturing elevated for quarters, not weeks. BA and RTX benefit indirectly from the same production ramps and aftermarket normalization, while LMT and smaller missile/space suppliers may see similar multi-year content expansion; the near-term loser is any supplier with fixed-price legacy contracts and slower repricing cadence, because RBC is effectively showing that inflation recovery is still incomplete.

The contrarian angle is that the post-earnings drawdown may be overdone relative to the forward setup. The market appears to be punishing valuation more than fundamentals, but this is exactly the kind of name where a 1-2 quarter bridge from backlog to revenue can re-accelerate sentiment once investors see margin flow-through and debt paydown continue. The key catalyst is not the next beat; it is evidence that capacity additions are converting into sustained incremental revenue without margin erosion, especially through the next two quarters.

From a risk perspective, the tape can stay broken in the near term if investors use the premium multiple as an excuse to de-risk anything with defense exposure. But over 6-12 months, the combination of backlog visibility, deleveraging, and pricing reset argues that the downside is more likely a function of multiple compression than fundamental deterioration.

Key Decisions for Investors

• Long RBC on weakness over the next 1-2 trading sessions: use the post-earnings flush as entry for a 3-6 month hold; target a re-rating if the stock stabilizes and management shows no margin slippage. Risk/reward is attractive because the selloff is multiple-driven, not thesis-breaking.
• Pair trade: long RBC / short BA for 1-3 months. RBC has clearer backlog-to-FCF conversion and direct pricing leverage, while BA still carries more execution and balance-sheet risk; this pair isolates defense/industrial supply-chain strength without taking broad market beta.
• Buy LMT or RTX as a read-through basket against short-duration weakness in RBC if you want cleaner defense exposure. If defense spending momentum continues, primes should catch the next leg of capex and procurement optimism within 1-2 quarters.
• Consider selling cash-secured puts on RBC 5-10% below spot with a 1-2 month tenor. The implied-vol premium should remain elevated after the selloff, and you get paid to wait for the market to recognize the backlog/deleveraging runway.
• Avoid chasing the first bounce; wait for either a failed breakdown or confirmation that the stock can reclaim its pre-earnings gap within 5-10 sessions. If it cannot, the market is likely still de-rating the multiple and a patient entry is better.